<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298515</url>
  </required_header>
  <id_info>
    <org_study_id>HNEAH-KAEK 2019/100</org_study_id>
    <nct_id>NCT04298515</nct_id>
  </id_info>
  <brief_title>Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity</brief_title>
  <official_title>Determination of the Relationship Between Nesfatin-1 Levels and Energy Intake Levels of Patients With Type 2 Diabetes, Insulin Resistance and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research was planned to determine the level of nesfatin-1, known as satiety hormone, in
      type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a
      relationship between patients' energy intake levels. Additionally, it was aimed to evaluate
      the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid
      concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be
      measured. In addition, patients' daily food consumption will be taken and the amount of
      energy they receive will be calculated daily. The relationship between the level of
      nesfatin-1 in the blood and the energy received will be examined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nefratin-1 in type 2 diabetes</measure>
    <time_frame>1 day (Blood will be drawn from patients once)</time_frame>
    <description>Blood will be drawn from type 2 diabates patients after 12 hours of fasting (n=45)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nefratin-1 in obesity</measure>
    <time_frame>1 day (Blood will be drawn from patients once)</time_frame>
    <description>Blood will be drawn from obesity patients after 12 hours of fasting (n=45)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nefratin-1 in insulin resistance</measure>
    <time_frame>1 day (Blood will be drawn from patients once)</time_frame>
    <description>Blood will be drawn from insulin resistance patients after 12 hours of fasting (n=45)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <condition>Nesfatin-1</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin resistance group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obesity group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nesfatin-1</intervention_name>
    <description>Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level</description>
    <arm_group_label>Insulin resistance group</arm_group_label>
    <arm_group_label>Obesity group</arm_group_label>
    <arm_group_label>Type 2 Diabetes group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Insulin resistance

          -  Obesity disease

        Exclusion Criteria:

          -  Pediatric individuals

          -  All patients who are hospitalized,

          -  Liver disease

          -  Cancer patients

          -  Disease related to the gastrointestinal tract

          -  Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic
             syndrome

          -  Neurological disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gülin Öztürk Özkan, Assis Prof</last_name>
    <role>Study Chair</role>
    <affiliation>İstanbul Medeniyet University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kadir Kayataş, associate professor</last_name>
    <role>Study Director</role>
    <affiliation>Haydarpaşa Numune Education and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gülin Öztürk Özkan, Assis Prof</last_name>
    <phone>02162803333</phone>
    <email>glnzturk@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haydarpaşa Numune Education and Research Hospital</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gülin Öztürk Özkan, Assis Prof</last_name>
      <phone>02162803333</phone>
      <email>glnzturk@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1530%2FJOE-16-0361</url>
    <description>Review</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=19896982</url>
    <description>Original research</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.dsx.2014.04.010</url>
    <description>Original research</description>
  </link>
  <reference>
    <citation>Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol. 2017 Jan;232(1):R45-R65. Epub 2016 Oct 17. Review.</citation>
    <PMID>27754932</PMID>
  </reference>
  <reference>
    <citation>Mirzaei K, Hossein-nezhad A, Keshavarz SA, Koohdani F, Eshraghian MR, Saboor-Yaraghi AA, Hosseini S, Chamari M, Zareei M, Djalali M. Association of nesfatin-1 level with body composition, dietary intake and resting metabolic rate in obese and morbid obese subjects. Diabetes Metab Syndr. 2015 Oct-Dec;9(4):292-8. doi: 10.1016/j.dsx.2014.04.010. Epub 2014 May 25.</citation>
    <PMID>25470645</PMID>
  </reference>
  <results_reference>
    <citation>Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010 Jan 8;159(1-3):72-7. doi: 10.1016/j.regpep.2009.11.003.</citation>
    <PMID>19896982</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Gülin Öztürk Özkan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Obesity</keyword>
  <keyword>Nesfatin-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

